サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：希少疾患診断市場- 世界の産業規模、シェア、動向、機会、予測、2017年-2027年、適応症別、形質タイプ別、検査タイプ別、技術別、サンプルタイプ別、エンドユーザー別、企業別、地域別セグメント
市場調査レポート
商品コード
1289657

希少疾患診断市場- 世界の産業規模、シェア、動向、機会、予測、2017年-2027年、適応症別、形質タイプ別、検査タイプ別、技術別、サンプルタイプ別、エンドユーザー別、企業別、地域別セグメント

Rare Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Indication, By Trait Type, By Test Type, By Technology, By Sample Type, By End User, By company and By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 117 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

希少疾患診断市場- 世界の産業規模、シェア、動向、機会、予測、2017年-2027年、適応症別、形質タイプ別、検査タイプ別、技術別、サンプルタイプ別、エンドユーザー別、企業別、地域別セグメント
出版日: 2023年06月01日
発行: TechSci Research
ページ情報: 英文 117 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の希少疾患診断市場は、予測期間2023-2027年に目覚ましい成長を遂げると予測されています。

主な要因としては、希少疾患の発生率の増加、先端技術の採用、研究開発への投資の増加などがあり、市場の成長を促しています。希少疾患や希少疾病とは、人口のごく一部が罹患するあらゆる疾病を指します。その他の市場成長要因としては、認知度向上のための政府の取り組み、希少疾患の患者登録の拡大、シーケンシング費用の低下、高齢者人口の増加、希少疾患診断に関するプログラムおよび新製品開発の増加、研究開発活動の活発化が挙げられます。

希少疾患の発生率の上昇は、市場の成長を促進します。

希少疾患は、その疾患に罹患している人がたくさんいるため、希少とは言えません。希少疾患は、エイズとがんの組み合わせよりも多くの人々に影響を与えます。例えば、European Journal of Human Geneticsによると、希少疾患に罹患している人の数は、全世界で3億人と推定されています。アガマグロブリン血症、グッドパスチャー症候群、多発血管炎性肉芽腫症（GPA、旧ウェゲナー肉芽腫症）、白血球接着欠損症、小児ブルトン・アガマグロブリン血症、小児重症複合免疫不全症、シュニッツラー症候群などの希少疾患に苦しむ人々の増加を受けて、診断に対する需要の急増が市場成長を後押ししています。

疾患診断の技術的進歩

希少疾病診断分野における先端技術の採用が増加し、市場の成長を後押ししています。人工知能（AI）、NGSベースの検査、自動化技術などの新しい革新的な技術や進歩は、標準的な手動分析と比較して、時間とコストを削減し、より正確な診断を可能にするのに役立っています。例えば、ホールエクソームシーケンス（WES）遺伝子検査ツールの採用が増加しています。この技術は、全ゲノムの1～2%を占めるエクソンのみを対象とし、病気を引き起こす変異の80%を含んでいます。

希少疾病の診断に対する意識の高まり

希少疾患の早期診断は、人々が苦しむことなくタイムリーに治療するのに役立つため、不可欠です。そのため、一般市民や患者の間で希少疾病に対する認識が高まっていることが、市場の成長を促進しています。政府や非政府組織による様々な取り組みが、病気の早期診断や治療について人々に認識させるために行われています。例えば、毎年NIHで開催される希少疾患デーでは、希少疾患とそれが患者の生活に与える影響について認識を高めることを目的としています。

利用可能なカスタマイズ

TechSciリサーチは、与えられた市場データをもとに、企業の特定のニーズに応じてカスタマイズを提供します。本レポートでは、以下のカスタマイズが可能です：

企業情報

  • 追加市場プレイヤー（最大5社）の詳細な分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の希少疾患診断市場に与える影響

第5章 顧客の声

第6章 希少疾患診断の世界市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 適応症別（消化器疾患、内分泌・代謝疾患、循環器疾患、血液・腫瘍疾患、その他）
    • 形質タイプ別（遺伝性／後天性）
    • 検査タイプ別（遺伝子検査、一般臨床検査、画像診断、その他）
    • 技術別（次世代シーケンサー、全ゲノムシーケンス、全エクソームシーケンス、マイクロアレイ、その他）
    • サンプルタイプ別（DNAサンプル、血液サンプル、唾液サンプル、その他）
    • エンドユーザー別（病院・クリニック、学術・研究機関、その他）
    • 地域別
    • 企業別（2021年）
  • 市場マップ

第7章 北米の希少疾患診断市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 適応症別
    • 形質タイプ別
    • 検査タイプ別
    • 技術別
    • サンプルタイプ別
    • エンドユーザー別
    • 国別
  • 北米の場合国別分析
    • 米国
    • カナダ
    • メキシコ

第8章 欧州の希少疾患診断市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 適応症別
    • 形質タイプ別
    • 検査タイプ別
    • 技術別
    • サンプルタイプ別
    • エンドユーザー別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋の希少疾患診断市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 適応症別
    • 形質タイプ別
    • 検査タイプ別
    • 技術別
    • サンプルタイプ別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域の国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第10章 南米の希少疾患診断市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 適応症別
    • 形質タイプ別
    • 検査タイプ別
    • 技術別
    • サンプルタイプ別
    • エンドユーザー別
    • 国別
  • 南米の国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカの希少疾患診断市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 適応症別
    • 形質タイプ別
    • 検査タイプ別
    • 技術別
    • サンプルタイプ別
    • エンドユーザー別
    • 国別
  • MEA：国別分析
    • 南アフリカ希少疾病診断薬
    • サウジアラビア希少疾病診断薬
    • UAE希少疾病診断薬

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向市場の動向と開拓

第14章 競合情勢（SWOT分析も含む）

  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • QIAGEN NV
  • PerkinElmer, Inc
  • Quest Diagnostics, Inc.
  • CENTOGENE N.V.
  • 23andMe, Inc.
  • 3billion, Inc.
  • Eurofins Scientific SE
  • Invitae Corporation

第15章 戦略的提言

目次
Product Code: 13047

The global rare disease diagnostics market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include the growing incidence of rare disorders, adoption of advanced technology, and increase in investments in R&D are impelling the growth of the market. Rare diseases or orphan diseases is any disease that affects a small percentage of the population. The other factors supporting the market's growth are, increasing government initiatives for spreading awareness, expanding patient registry for rare diseases, declining sequencing cost, rising geriatric population, the growing launch of programs & new product development in rare disease diagnosis, and rise in research and development activities.

The rising incidence of rare disorders will fuel the market growth.

Rare diseases are not rarer as there are many people who are suffering from the disease. They affect more people than the combination of AIDS & Cancer. For instance, as per the European Journal of Human Genetics, the number of people living with a rare disease is estimated at 300 million across the globe. Owing to the rise in the number of people suffering from rare diseases such as Agammaglobulinemia, Goodpasture Syndrome, Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis), Leukocyte Adhesion Deficiency, Pediatric Bruton Agammaglobulinemia, Pediatric Severe Combined Immunodeficiency, Schnitzler Syndrome and others, the surge in demand for the diagnosis is bolstering the growth of the market.

Technological Advancements in Disease Diagnosis

The rise in the adoption of advanced technology in the field of rare diseases diagnostic is augmenting the growth of the market. New innovative technologies and advancements such as artificial intelligence (AI), NGS-based testing, and automation technology are assisting in reducing time and cost and enabling more accurate diagnosis when compared to standard manual analysis. For instance, increase in the adoption of the Whole Exome Sequencing (WES) genetic testing tool. The technique aims only at exons, which make 1-2% of the whole genome and include 80% of all disease-causing mutations.

Rising Awareness of diagnosis of rare diseases

Early diagnosis of rare diseases is essential as it can help people to treat these conditions timely without suffering. Thus, the rise in awareness about rare diseases among the general public and patients is facilitating the growth of the market. Various initiatives by government and non-government organizations are taken to make people aware of the early diagnosis and treatment of the disease. For instance, every year, rare diseases day at NIH takes place, which aims to raise awareness about rare diseases and the impact they have on patient's lives.

Market Segmentation

The global rare disease diagnostics market is segmented into indication, trait type, test type, technology, sample type, end user, and company. Based on indication, the market is divided into gastroenterology disease, endocrine & metabolism disorders disease, cardiovascular disorders, hematology & oncology disease, and others. Based on trait type, the market is divided into inherited and acquired. Based on test type, the market is segmented into genetic tests, general lab tests, diagnostic imaging, and others. Based on technology, the market is divided into next-generation sequencing, whole genome sequencing, whole exome sequencing, microarrays, and others. Based on sample type, the market is divided into DNA samples, blood sample, saliva samples, and others. Based on end-user, the market is divided into hospitals & clinics, academic & research institutes, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising occurrences of rare diseases in the country.

Market Players

Agilent Technologies, Inc., Illumina, Inc., QIAGEN NV, PerkinElmer, Inc, Quest Diagnostics, Inc., CENTOGENE N.V., 23andMe, Inc., 3billion, Inc., Eurofins Scientific SE, and Invitae Corporation are some of the leading companies operating in the market.

Report Scope

In this report, global rare disease diagnostics market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rare Disease Diagnostics Market, By Indication:

  • Gastroenterology Disease
  • Endocrine & Metabolism Disorders Disease
  • Cardiovascular Disorders
  • Hematology & Oncology Disease
  • Others

Rare Disease Diagnostics Market, By Trait Type:

  • Inherited
  • Acquired

Rare Disease Diagnostics Market, By Test Type:

  • Genetic Tests
  • General Lab Tests
  • Diagnostic Imaging
  • Others

Rare Disease Diagnostics Market, By Technology:

  • Next Generation Sequencing
  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Microarrays
  • Others

Rare Disease Diagnostics Market, By Sample Type:

  • DNA Sample
  • Blood Sample
  • Saliva Sample
  • Others

Rare Disease Diagnostics Market, By End User:

  • Hospitals & Clinics
  • Academic & Research Institutes
  • Others

Rare Disease Diagnostics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Rare Disease Diagnostics Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Rare Disease Diagnostics Market

5. Voice of Customer

6. Global Rare Disease Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication (Gastroenterology Disease, Endocrine & Metabolism Disorders Disease, Cardiovascular Disorders, Hematology & Oncology Disease, Others)
    • 6.2.2. By Trait Type (Inherited v/s Acquired)
    • 6.2.3. By Test Type (Genetic Tests, General Lab Tests, Diagnostic Imaging, Others)
    • 6.2.4. By Technology (Next Generation Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays, Others)
    • 6.2.5. By Sample Type (DNA Sample, Blood Sample, Saliva Sample, Others)
    • 6.2.6. By End User (Hospitals & Clinics, Academic & Research Institutes, Others)
    • 6.2.7. By Region
    • 6.2.8. By Company (2021)
  • 6.3. Market Map

7. North America Rare Disease Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Trait Type
    • 7.2.3. By Test Type
    • 7.2.4. By Technology
    • 7.2.5. By Sample Type
    • 7.2.6. By End User
    • 7.2.7. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Rare Disease Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Trait Type
        • 7.3.1.2.3. By Test Type
        • 7.3.1.2.4. By Technology
        • 7.3.1.2.5. By Sample Type
        • 7.3.1.2.6. By End User
    • 7.3.2. Canada Rare Disease Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Trait Type
        • 7.3.2.2.3. By Test Type
        • 7.3.2.2.4. By Technology
        • 7.3.2.2.5. By Sample Type
        • 7.3.2.2.6. By End User
    • 7.3.3. Mexico Rare Disease Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Trait Type
        • 7.3.3.2.3. By Test Type
        • 7.3.3.2.4. By Technology
        • 7.3.3.2.5. By Sample Type
        • 7.3.3.2.6. By End User

8. Europe Rare Disease Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Trait Type
    • 8.2.3. By Test Type
    • 8.2.4. By Technology
    • 8.2.5. By Sample Type
    • 8.2.6. By End User
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Rare Disease Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Trait Type
        • 8.3.1.2.3. By Test Type
        • 8.3.1.2.4. By Technology
        • 8.3.1.2.5. By Sample Type
        • 8.3.1.2.6. By End User
    • 8.3.2. Germany Rare Disease Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Trait Type
        • 8.3.2.2.3. By Test Type
        • 8.3.2.2.4. By Technology
        • 8.3.2.2.5. By Sample Type
        • 8.3.2.2.6. By End User
    • 8.3.3. United Kingdom Rare Disease Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Trait Type
        • 8.3.3.2.3. By Test Type
        • 8.3.3.2.4. By Technology
        • 8.3.3.2.5. By Sample Type
        • 8.3.3.2.6. By End User
    • 8.3.4. Italy Rare Disease Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Trait Type
        • 8.3.4.2.3. By Test Type
        • 8.3.4.2.4. By Technology
        • 8.3.4.2.5. By Sample Type
        • 8.3.4.2.6. By End User
    • 8.3.5. Spain Rare Disease Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Trait Type
        • 8.3.5.2.3. By Test Type
        • 8.3.5.2.4. By Technology
        • 8.3.5.2.5. By Sample Type
        • 8.3.5.2.6. By End User

9. Asia-Pacific Rare Disease Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Trait Type
    • 9.2.3. By Test Type
    • 9.2.4. By Technology
    • 9.2.5. By Sample Type
    • 9.2.6. By End User
    • 9.2.7. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Rare Disease Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Trait Type
        • 9.3.1.2.3. By Test Type
        • 9.3.1.2.4. By Technology
        • 9.3.1.2.5. By Sample Type
        • 9.3.1.2.6. By End User
    • 9.3.2. India Rare Disease Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Trait Type
        • 9.3.2.2.3. By Test Type
        • 9.3.2.2.4. By Technology
        • 9.3.2.2.5. By Sample Type
        • 9.3.2.2.6. By End User
    • 9.3.3. Japan Rare Disease Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Trait Type
        • 9.3.3.2.3. By Test Type
        • 9.3.3.2.4. By Technology
        • 9.3.3.2.5. By Sample Type
        • 9.3.3.2.6. By End User
    • 9.3.4. South Korea Rare Disease Diagnostics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Indication
        • 9.3.4.2.2. By Trait Type
        • 9.3.4.2.3. By Test Type
        • 9.3.4.2.4. By Technology
        • 9.3.4.2.5. By Sample Type
        • 9.3.4.2.6. By End User
    • 9.3.5. Australia Rare Disease Diagnostics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Indication
        • 9.3.5.2.2. By Trait Type
        • 9.3.5.2.3. By Test Type
        • 9.3.5.2.4. By Technology
        • 9.3.5.2.5. By Sample Type
        • 9.3.5.2.6. By End User

10. South America Rare Disease Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Trait Type
    • 10.2.3. By Test Type
    • 10.2.4. By Technology
    • 10.2.5. By Sample Type
    • 10.2.6. By End User
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Rare Disease Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Trait Type
        • 10.3.1.2.3. By Test Type
        • 10.3.1.2.4. By Technology
        • 10.3.1.2.5. By Sample Type
        • 10.3.1.2.6. By End User
    • 10.3.2. Argentina Rare Disease Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Trait Type
        • 10.3.2.2.3. By Test Type
        • 10.3.2.2.4. By Technology
        • 10.3.2.2.5. By Sample Type
        • 10.3.2.2.6. By End User
    • 10.3.3. Colombia Rare Disease Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Trait Type
        • 10.3.3.2.3. By Test Type
        • 10.3.3.2.4. By Technology
        • 10.3.3.2.5. By Sample Type
        • 10.3.3.2.6. By End User

11. Middle East and Africa Rare Disease Diagnostics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Indication
    • 11.2.2. By Trait Type
    • 11.2.3. By Test Type
    • 11.2.4. By Technology
    • 11.2.5. By Sample Type
    • 11.2.6. By End User
    • 11.2.7. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Rare Disease Diagnostics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Indication
        • 11.3.1.2.2. By Trait Type
        • 11.3.1.2.3. By Test Type
        • 11.3.1.2.4. By Technology
        • 11.3.1.2.5. By Sample Type
        • 11.3.1.2.6. By End User
    • 11.3.2. Saudi Arabia Rare Disease Diagnostics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Indication
        • 11.3.2.2.2. By Trait Type
        • 11.3.2.2.3. By Test Type
        • 11.3.2.2.4. By Technology
        • 11.3.2.2.5. By Sample Type
        • 11.3.2.2.6. By End User
    • 11.3.3. UAE Rare Disease Diagnostics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Indication
        • 11.3.3.2.2. By Trait Type
        • 11.3.3.2.3. By Test Type
        • 11.3.3.2.4. By Technology
        • 11.3.3.2.5. By Sample Type
        • 11.3.3.2.6. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape (Inclusive of SWOT Analysis)

  • 14.1. Agilent Technologies, Inc.
  • 14.2. Illumina, Inc.
  • 14.3. QIAGEN NV
  • 14.4. PerkinElmer, Inc
  • 14.5. Quest Diagnostics, Inc.
  • 14.6. CENTOGENE N.V.
  • 14.7. 23andMe, Inc.
  • 14.8. 3billion, Inc.
  • 14.9. Eurofins Scientific SE
  • 14.10. Invitae Corporation

15. Strategic Recommendations